COVERAGE HUB
$QURE
4 articles in last 30 days
LAST 30 DAYS
4 articles
AVG GRADE
HIGH
score: 0.62
SENTIMENT
BULLISH
TOTAL VIEWS
1
RECENT COVERAGE · 4 ARTICLES
UniQure: AMT-130's FDA Path Reaffirms My Bull Case (NASDAQ:QURE)
UniQure (QURE) has received a regulatory tailwind with the FDA's decision to reopen the Biologics License Application (BLA) pathway for...
uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring (NASDAQ:QURE)
uniQure (QURE) received a significant regulatory milestone when the FDA accepted Phase 1/2 data for AMT-130 under accelerated approval...
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency
QURE is moving forward with FDA approval pursuit for its Huntington's disease gene therapy despite prior regulatory friction. This...
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
uniQure (QURE) announced a path toward Biologics License Application (BLA) submission for AMT-130, its gene therapy candidate for...